期刊文献+

病原体灭活技术在血液成分中的应用进展及质量评价 被引量:2

Advances of pathogen inactivation technology in blood components and quality evaluation
下载PDF
导出
摘要 通过献血者筛查、病原体抗原抗体检测、核酸检测的全覆盖,感染性输血风险已降至极低水平,病原体灭活技术(PRT)在保障血液安全方面发挥了不可替代的作用。理想的PRT除了能有效去除血液中的目标病原体外,更重要的是能够最大限度地保持血液中有效成分的活性、不影响被处理血液成分的治疗效果。本文主要对病原体灭活技术的发展进行概述,并讨论了病原体灭活处理对血液成分质量的影响,为改进或开发新的处理技术提供了参考。 Through the screening of blood donors,detection of pathogen antigen and antibody,full coverage of nucleic acid detection,the risk of infectious blood transfusion has been reduced to a very low level.Especially,pathogen inactivation technology(PRT)has played an irreplaceable role in ensuring blood safety.The best way to inactivate pathogens is not only to effectively remove the target pathogens in the blood,but also to maintain the activity of active ingredients in the blood to the maximum extent,and it doesn′t affect the effect of blood therapy.In this paper,the development of pathogen inactivation technology is summarized,and the influence of pathogen inactivation treatment on the quality of blood components is discussed.It provides references for improving or developing new processing technology.
作者 官笑羽 莫秋红 李玲 刘忠 GUAN Xiaoyu;MO Qiuhong;LI Ling;LIU Zhong(Institute of Blood Transfusion,Chinese Academy of Medical Sciences&Peking Union Medical College,Chengdu 610052,China;Key Laboratory of Transfusion Adverse Reactions,CAMS;Anhui Medical University;Nanning Central Blood Station)
出处 《中国输血杂志》 CAS 2021年第8期930-935,共6页 Chinese Journal of Blood Transfusion
基金 中国医学科学院创新工程项目,恢复期血浆及IVIG治疗新冠病毒肺炎的临床应用研究(2020-I2M-CoV19-006) 四川省科技厅项目,新冠肺炎的恢复期血浆临床应用研究(2020YFS0583)。
关键词 病原体灭活技术 血液成分 质量评价 pathogen inactivation technology blood composition quality evaluation
  • 相关文献

参考文献8

二级参考文献108

  • 1黄毅,王憬惺.血液细胞成分病原体灭活技术及效果评价[J].中国输血杂志,2004,17(3):206-210. 被引量:8
  • 2王迅.核酸检测技术(NAT)及其在血液筛检中的应用[J].中国输血杂志,2004,17(6):465-468. 被引量:30
  • 3王憬惺.血细胞成分病毒去除和灭活研究进展[J].国外医学(输血及血液学分册),1994,17(3):132-135. 被引量:7
  • 4李瑞兰,李忠平.HTLV传播及流行现状[J].临床输血与检验,2005,7(3):235-238. 被引量:26
  • 5肖云贵,许金波.血液病毒灭活机理及其效果评价[J].中国输血杂志,2005,18(5):425-427. 被引量:10
  • 6Cazenave JP,Davis K,Corash L.Design of clinical trials to evaluate the efficacy of platelet transfusion:the euroSPRITE trial for components treated with Helinx technology. Semi Hematol,2001,38(4 Suppl. 11):46
  • 7Goodrich RP.The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang,2001,78(Suppl. 2):211
  • 8Corash L.Inactivation of infectious pathogens in labile blood componets:meeting the challenge. Transfus Clin Biol,2001,8(3):138
  • 9Zavizion B,Serebryanik D,Sere bryan ikI,et al.Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion,2003,43(2):135
  • 10Mc Cullough J,Vesole D,Benjamin RJ,et al.Pathogen inactivated platelets (plt) using HelinxTM technology (Intercept plt) are hemostatically effective in thrombocytopenic patients (tcp pts):The SPRINT Trial.Blood,2001,98(11):450a(abstract)

共引文献44

同被引文献23

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部